Published in Hematology Week, November 14th, 2005
Financial details and other terms of the agreement are confidential. The Carmeda AB leadership team and workforce will remain in its existing facility in Upplands Vasby, Sweden.
The Carmeda BioActive Surface (CBAS) mimics the non-thrombogenic properties of the endothelial lining of blood vessels using a patented "end-point attachment" covalent bonding of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hematology Week